. 2021 Sep 1;110(6):1547–1557. doi: 10.1002/cpt.2384

Table 2.

Observed and predicted midazolam C_max and AUC ratios

	C_max ^a	C_max ratio^b	AUC_last ^a	AUC_last ratio^b
Observed
without risdiplam (n = 27)	7.65 (48.5%)	n.a	19.9 (49.0%)	n.a
with risdiplam (n = 26)	8.96 (40.4%)	1.16 (1.06–1.28)	22.0 (47.7%)	1.11 (1.02–1.20)
Predicted^c
without risdiplam	7.51 (70%)	n.a.	22.8 (64%)	n.a
with risdiplam
in vitro k _inact = 3.91/hour	13.2 (67%)	1.76 (+52%)^f	48.4 (73%)	2.12 (+91%)^f
in vivo k _inact ^d = 0.39/hour	8.72 (70%)	1.16 (0%)^f	27.0 (66%)	1.19 (+7.0%)^f
in vivo k _inact ^e = 0.22/hour	8.32 (70%)	1.11 (−4.0%)^f	25.6 (65%)	1.12 (+1.0%)^f

Observed and predicted midazolam C_max and AUC ratios using in vitro and estimated in vivo k _inact values.

AUC_last, area under the plasma concentration‐time curve from time zero to time of last measurable concentration; C_max, maximum concentration; k _inact, inactivation constant; n.a, not applicable.

^aGeometric mean (coefficient of variation, CV%). ^bGeometric least squares means are presented. ^cPredicted by the PBPK models. ^d1/10 of the in vitro k _inact. ^e1/18 of the in vitro k _inact. ^f% difference from the corresponding observed values. Number ranges in parentheses are 90% confidence intervals.